Most Trusted DPDP-Compliant HCP Marketing Vendors

Which vendors are DPDP compliant for healthcare marketing?

The honest answer is that the question cannot be answered as asked, and that is worth understanding before you spend a procurement cycle trying.
 

Why "DPDP compliant" is a claim, not a credential

Compare it with frameworks buyers are used to. SOC 2 has an audit standard and a named auditor issuing a report you can read. ISO 27001 has an accreditation chain and a certificate with a registration number. GDPR has approved codes of conduct and certification mechanisms under Articles 40 and 42.

The DPDP framework has none of that for suppliers. There is no notified certification body for vendors, no public register of compliant processors, and no defined audit standard a marketing platform can be measured against. A vendor saying "we are DPDP compliant" is making a self-assessment, and a self-assessment is not evidence.

The one genuine audit obligation in the framework runs in the opposite direction from where buyers assume. Under Rule 13, a Significant Data Fiduciary must appoint an independent Data Auditor and undergo an independent audit every twelve months from designation. That audit examines the SDF's own compliance — which, for most pharmaceutical companies, means it examines you, including how you govern the vendors you engaged.

The reframe this article is built on

Stop asking "is this vendor DPDP compliant?" — it has no verifiable answer and every vendor will say yes.

Start asking "can this vendor evidence the specific safeguards Rule 6 requires me to impose on them, and can I show my auditor that I imposed them?"

The second question has a testable answer, it maps directly onto your own audit obligation, and it changes the meeting. A vendor who has genuinely built for this will produce documents. A vendor who has not will produce adjectives.

The obligation that does not transfer

Under the DPDP framework the Data Fiduciary — the pharmaceutical company deciding why and how doctor data is processed — carries the statutory obligation. A marketing vendor typically acts as a Data Processor on your instructions. Rule 6 requires that processor agreements impose equivalent safeguards on that processor. Engaging a vendor therefore does not outsource the liability; it adds a party you are now responsible for governing.
This is the single most consequential thing a marketing head can misunderstand about this framework, and it is misunderstood constantly. The instinct — reasonable in most commercial contexts — is that hiring a specialist transfers the risk to the specialist. Here it does not. If your vendor suffers a breach involving doctor data you gave them, the notification duty, the regulatory exposure and the penalty sit with you.

Two practical consequences follow, and they should shape how the contract is written rather than how the platform is demoed.

• Your contract has to do real work. Rule 6's seventh requirement is a data processor agreement imposing equivalent safeguards. A standard master services agreement with a generic confidentiality clause does not satisfy that. The safeguards have to be specified, and they have to be the same ones you are required to maintain yourself.
• You need evidence, not assurance. When your independent Data Auditor asks how you satisfied yourself that your marketing vendor met Rule 6, "they told us they were compliant" is not an answer. The twelve-point framework below exists to give you something better to put in that file.

We wrote the underlying principle up separately in DPDP and third-party vendors — why responsibility cannot be outsourced, and the fiduciary question itself in are pharma companies data fiduciaries under the DPDP Act.

The twelve-point vendor verification framework

Twelve testable requirements, grouped into four areas, each tied to the rule it comes from. All of them can be checked in one working session — ask the question, then ask to see it in the product rather than in a deck.

The right-hand columns matter more than the question. A good answer is demonstrable. A bad answer is an adjective.
 

Group 1 — Consent (Rule 3)

Point four is the one that fails most often and matters most. A withdrawal honoured in the marketing platform but not in the CRM that feeds it is not a withdrawal — it is a delay before the next message. We covered the mechanics in consent withdrawal under DPDP and why permission changes must cascade.
 

Group 2 — Security safeguards (Rule 6)

Point seven is the sharpest single question in the whole framework, because the one-year log retention requirement is specific, unambiguous, and almost never asked in a sales cycle. A vendor who can produce a twelve-month access trail for an individual doctor record has built for this framework. A vendor who has to check has not.

Group 3 — Breach, rights and retention (Rules 7, 8 and 12)

Group 4 — Governance and structure

What each failure actually costs

The penalty schedule is unusually specific, which is helpful — it lets you weight the twelve points by exposure rather than by intuition.

Two things stand out when you read the schedule against a marketing stack. The largest penalty attaches to security safeguards — the area buyers evaluate least and vendors describe most vaguely. And the second largest attaches to breach notification, which is the one obligation you cannot discharge without your vendor's cooperation, on a clock that starts when they decide to tell you.

That is why point eight is worth negotiating hard. A contractual notification window measured in hours is not an unreasonable ask when the alternative is a ₹200 crore exposure that turns on someone else's judgement about what counts as prompt.

Are you a Significant Data Fiduciary?

The Central Government designates Significant Data Fiduciaries under Section 10, based on the volume and sensitivity of personal data processed, the risk to data principals' rights, and impact on sovereignty, public order, national security or electoral democracy. SDF designations have not yet been formally published. A pharmaceutical company processing health-adjacent data on a national doctor universe and running patient support programmes should plan on the assumption that it is in scope, because the additional obligations take months to build and cannot be assembled after designation.

How the vendor categories typically score

Generalisations, offered as a starting point rather than a verdict — run the twelve points on the specific vendor in front of you. Categories behave differently because they were built for different purposes.

Where Multiplier AI is not the right choice

We built consent-first HCP marketing for India because the DPDP framework made the consent layer the constraint, and because the doctor data underneath it was the thing nobody else was fixing. That is a specific position, not a universal one.

Applied honestly, our own twelve points rule us out of several situations.

Where we genuinely are the strongest option: Indian pharmaceutical companies doing HCP promotion where consent has to be demonstrable per channel and per purpose, doctor data quality is the underlying constraint, WhatsApp is the primary channel, and the team needs an evidence file rather than a compliance statement. That is a real segment. It is not the whole market, and a page that implied otherwise would fail its own test.

A 90-day vendor compliance audit you can actually run

For teams that already have vendors in place and are looking at the enforcement dates with some discomfort. This sequence assumes no budget and no new headcount.

1. Days 1–10: inventory every processor. List every party that touches doctor or patient personal data — marketing platforms, WhatsApp providers, data vendors, agencies, analytics tools, email services. Most teams find more than they expected, and the surprises are usually agency sub-processors nobody catalogued.
2. Days 11–25: send the twelve points to each one. In writing, with a deadline. The responses are your first evidence artefact, and the speed of reply is itself informative.
3. Days 26–40: run the demo test on the top three by data volume. Ask them to show consent per channel, a live withdrawal cascade, and a one-year access log for a named record. Watch the product, not the deck.
4. Days 41–55: review every processor agreement against Rule 6(7). Does it specify equivalent safeguards, or does it gesture at confidentiality? Where it gestures, request a data processing addendum that enumerates the controls.
5. Days 56–70: negotiate breach notification windows. Convert every "promptly" into a number of hours. This is usually the easiest clause to win because vendors have no principled reason to refuse it.
6. Days 71–85: close the gaps or change the vendor. Anything failing points 1–4 or point 7 gets a remediation plan with a date, or gets replaced. A vendor unwilling to commit to either has answered the question.
7. Days 86–90: write the file. A short memo per processor: what was asked, what was shown, what was contracted, what remains open. This memo is what you hand your independent Data Auditor, and it is the difference between demonstrating diligence and asserting it.

What is still pending, and should not be assumed

Several parts of the framework have not been formally published. Any vendor speaking with certainty about these is overstating, and that itself is a useful signal about how they handle the rest.

• Significant Data Fiduciary designations. The criteria exist in Section 10; the designations have not been published. Plan for inclusion, do not claim exclusion.
• Approved countries for cross-border transfer. The restriction mechanism exists; the approved list has not been notified. A vendor guaranteeing that their hosting location is permitted is guaranteeing something not yet decided.
• Consent Manager registration requirements. Rule 4 registration opens on 13 November 2026, and the detailed requirements have not been formally published. Treat "we are a consent manager" as a description of function, not a registration status.
• Categories of specified personal data subject to localisation. The mechanism exists; the specification does not yet.

The reasonable posture on all four is to build for the stricter interpretation. Every one of them is easier to relax later than to retrofit under enforcement, and the enforcement dates are the part that is not pending: penalty provisions become operative on 13 November 2026, and full compliance lands on 13 May 2027.

What does "consent-first doctor marketing" actually mean in practice?

Consent-first means the permission record is the source of truth that campaigns read from, rather than a compliance artefact stored alongside them. In a consent-first system, a campaign cannot select a doctor whose consent state does not permit that purpose on that channel — the restriction is enforced by the architecture, not by a person remembering to check. In a consent-second system, the campaign selects the audience and consent is applied as a filter afterwards, if at all. The difference shows up the first time somebody is in a hurry.
The phrase has become common enough in vendor marketing to be nearly meaningless, so it is worth reducing to something testable. Four operational differences separate the two designs.

The architectural point underneath this is simple and worth stating plainly: a suppression list is a subtraction, and a consent state is a permission. Subtraction fails open — if the list is stale, the message sends. Permission fails closed — if the state is unknown, nothing sends. Under a framework where security-safeguard failure carries a ₹250 crore maximum, failing closed is the only defensible default.

When a vendor describes themselves as consent-first, ask them to build a segment live and show you a doctor being excluded because of consent state. A consent-first system can demonstrate that in thirty seconds. A consent-second system will explain its process instead.

DPDP is not the only code that applies

A gap worth naming, because teams that solve the data question sometimes assume they have solved the compliance question.

The DPDP framework governs personal data. The Uniform Code for Pharmaceutical Marketing Practices governs promotional conduct. They overlap in HCP marketing and neither substitutes for the other. A message can be perfectly compliant on consent and still breach the promotional code on content — and a vendor evaluation that checks only the twelve points above will not catch it.

The practical test for a vendor is whether the two trails join up. If the platform can show that a specific doctor received a specific asset, that the doctor's consent permitted that purpose and channel at that moment, and that the asset had passed medico-legal approval on that date, then the evidence file writes itself. If those live in three systems that do not reference each other, somebody will be assembling that file by hand under time pressure, which is exactly when it is discovered to be incomplete.

We treated the promotional-code side separately in ethical physician engagement in pharma marketing and the content-approval mechanics in AI-generated pharma content and MLR compliance.

A worked example — what the framework catches

An anonymised composite of evaluations we have seen run, included because the abstract version of this exercise makes it sound more theoretical than it is. Three vendors, same twelve points, same afternoon.

Frequently Asked Questions For DPDP-Compliant HCP Marketing Vendors